Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VONVENDI in Chinese Subjects With Von Willebrand Disease
NCT07129343Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Oct 2025
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
A Phase 3 trial of vonicog alfa in von Willebrand disease (VWD), sponsored by Takeda. Started Oct 2025; status: recruiting.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NCT07129343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07129343.